On July 30, IMPACT Therapeutics announced an exclusive collaboration with global specialty pharma company Pharmanovia, granting rights to senaparib — a novel, highly potent PARP1/2 inhibitor — for maintenance monotherapy in advanced epithelial ovarian, fallopian tube and primary peritoneal cancers across Europe, the Middle East, North Africa, Australia and New Zealand.

The agreement is IMPACT's first major BD since its May Hong Kong IPO, advancing its global rollout. Worth up to €423.5 million — upfront, near-term regulatory and sales-threshold milestones plus tiered royalties up to the low-to-mid twenties percent — it extends senaparib to 66 countries: all 27 EU states, plus the UK, Nordics, Switzerland, Australia, New Zealand and MENA.

Senaparib's differentiated profile underpins the deal: its unique molecular structure delivers excellent target selectivity and a wide safety window, and it was approved by China's NMPA in January 2025 for first-line maintenance in ovarian cancer after platinum-based chemotherapy before joining the NRDL in January 2026. Among PARP inhibitors used for "all-population" first-line maintenance in Chinese ovarian cancer patients, it delivered the most favorable progression-free survival result, setting a new benchmark for the class. With the EMA MAA accepted in August 2025 and European approval expected in H2 2026, Pharmanovia can launch immediately via its established infrastructure.

For IMPACT, the deal validates pipeline value post-IPO, achieves global reach across 66 countries without building overseas commercial teams, and shares in long-term success through double-digit royalties.